Autologous T-Cells Transduced With The Lentiviral Lv-R11Kea Encoding T-Cell Receptor Targeting Patient-Specific Tumor-Associated Antigens

• SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting
  2024-517062-42-00 Phase III 3 countries Immatics US Inc.
• Treatment of patients with solid tumors with genetically modified patients' own T-cells, recognizing a particular tumor marker Recruiting
  2024-515114-41-00 Phase I (FiH) 1 country Immatics US Inc.

Showing 1–2 of 2 trials